Delta-9-tetrahydrocannabinol accumulation, metabolism and cell-type-specific adverse effects in aggregating brain cell cultures

Toxicology and Applied Pharmacology

Volumn 228, Issue 1, 2008, Pages 8-16

  Monnet Tschudi, Florianne ^a   Hazekamp, Arno ^b   Perret, Nicolas ^a   Zurich, Marie Gabrielle ^a   Mangin, Patrice ^c   Giroud, Christian ^c   Honegger, Paul ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LEIDEN UNIVERSITY   (Netherlands)

^c University Hospital Center   (Switzerland)

Author keywords

11 Hydroxy delta 9 tetrahydrocannabinol (11 OH THC); 11 Nor 9 carboxy delta 9 tetrahydrocannabinol (THC COOH); Astrocytes; IL 6; Neurons; Oligodendrocytes; TNF

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 4 AMINOBUTYRIC ACID RECEPTOR; ARACHIDONYL 2 CHLOROETHYLAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABIS; CHOLINE ACETYLTRANSFERASE; DRONABINOL; GLUTAMATE AMMONIA LIGASE; GLUTAMATE DECARBOXYLASE; INTERLEUKIN 6; TETRAHYDROCANNABINOL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; EMBRYO; GLIA CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BRAIN; CANNABINOIDS; CELL AGGREGATION; CELLS, CULTURED; CHOLINE O-ACETYLTRANSFERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLUTAMATE DECARBOXYLASE; GTP PHOSPHOHYDROLASES; INTERLEUKIN-6; L-LACTATE DEHYDROGENASE; MASS SPECTROMETRY; NEUROGLIA; NEURONS; PREGNANCY; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REFERENCE STANDARDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOLVENTS; TETRAHYDROCANNABINOL; TUMOR NECROSIS FACTOR-ALPHA;

CANNABIS; RATTUS;

EID: 40849111595     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.11.007     Document Type: Article

References (54)

1. Achiron A., Miron S., Lavie V., Margalit R., and Biegon A. Dexanabinol (HU-211) effect on experimental auroimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunol. 102 (2000) 26-31
2. Arévalo-Martin A., Vela J.M., Molina-Holgado E., Borrell J., and Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 23 (2003) 2511-2516
3. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., and Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 (2000) 84-87
4. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., and Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15 (2001) 300-302
5. Baker D., Pryce G., Giovannini M.G., and Thompson A.J. The therapeutic potential of Cannabis. Lancet Neurol. 2 (2003) 291-298
6. Berdyshev E.V., Boichot E., Germain N., Allain N., Anger J.P., and Lagente V. Influence of fatty acid ethanolamides and delta-9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur. J. Pharmacol. 330 (1997) 231-240
7. Cabral G.A., and Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol. 78 (2005) 1192-1197
8. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., and Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol. 2 (2002) 69-82
9. 9-tetrahydrocannabinol. J. Neurosci. 18 (1998) 5322-5332
10. De Petrocellis L., Cascio M.G., and Di Marzo V. The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 141 (2004) 765-774
11. Eskes C., Honegger P., Jones-Lepp T., Varner K., Matthieu J.-M., and Monnet-Tschudi F. Neurotoxicity of dibutyltin in aggregating brain cell cultures. Toxicol. In Vitro 13 (1999) 555-560
12. Eskes C., Honegger P., Juillerat-Jeanneret L., and Monnet-Tschudi F. Microglial reaction induced by noncytotoxic methylmercury treatment leads to neuroprotection via interations with astrocytes and IL-6 release. Glia 37 (2002) 43-52
13. Facchinetti F., Del Giudice E., Furegato S., Passarotto M., and Leon A. Cannabinoids ablate release of TNF-α in rat microglial cells stimulated with lypopolysaccharide. Glia 41 (2003) 161-168
14. Favrat B., Menetrey A., Augsburger M., Rothuizen L.E., Appenzeller M., Buclin T., Pin M., Mangin P., and Giroud C. Two cases of "Cannabis acute psychosis" following the administration of oral Cannabis. BMC Psychiatry 5 (2005) 17
15. Giroud C., Michaud K., Sporkert F., Eap C., Augsburger M., Cardinal P., and Mangin P. A fatal overdose of cocaine associated with coingestion of marijuana, buprenorphine, and fluoxetine. Body fluid and tissue distribution of cocaine and its metabolites determined by hydrophilic interaction chromatography-mass spectrometry (HILIC-MS). J. Anal. Toxicol. 28 (2004) 464-474
16. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., and Uhl G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071 (2006) 10-23
17. Grotenhermen F. Cannabinoids in pain management. Cannabinoid receptor agonists will soon find their place in modern medicine. BMJ 323 (2001) 1250-1251
18. 1H-NMR. Chem. Pharm. Bull. (Tokyo) 52 (2004) 718-721
19. Hill E.L., Gallopin T., Ferezou I., Cauli B., Rossier J., Schweitzer P., and Lambolez B. Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J. Neurophysiol. 97 (2007) 2580-2589
20. Honegger P., and Monnet-Tschudi F. Aggregating neural cell cultures. In: Fedoroff S., and Richardson A. (Eds). Protocols for Neural Cell Cultures (2001), Humana Press, Inc., Totowa 199-218
21. Honegger P., and Schilter B. Serum-free aggregate cultures of fetal rat brain and liver cells: methodology and some practical applications in neurotoxicology. In: Zbinden G. (Ed). The Brain in Bits and Pieces. In Vitro Techniques in Neurobiology, Neuropharmacology and Neurotoxicology (1992), MTC Verlag, Zollikon, Switzerland 51-79
22. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International Union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
23. Huestis M.A., Henningfield J.E., and Cone E.J. Blood cannabinoids: I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J. Anal. Toxicol. 16 (1992) 276-282
24. Katona I., Sperlagh B., Sik A., Kafalvi A., Vizi E.S., Mackie K., and Freund T.F. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19 (1999) 4544-4558
25. Killestein J., Hoogervorst E.L., Reif M., Blauw B., Smits M., Uitdehaag B.M., Nagelkerken L., and Polman C.H. Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. J. Neuroimmunol. 137 (2003) 140-143
26. Klegeris A., Bissonnette C.J., and McGeer P.L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol. 139 (2003) 775-786
27. Koh J.Y., and Choi D.W. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J. Neurosci. Methods 20 (1987) 83-90
28. Kucera P., Cano E., Honegger P., Schilter B., Zijlstra J.A., and Schmid B. Validation of whole chick embryo cultures, whole rat embryo cultures and aggregating embryonic brain cell cultures using six pairs of coded compounds. Toxicol. In Vitro 7 (1993) 785-798
29. Kurihara T., and Tsukada Y. The regional and subcellular distribution of 2′,3′-cyclic nucleotide 3′-phosphohydrolase in the central nervous system. J. Neurochem. 14 (1967) 1167-1174
30. Lengacher S., Magistretti P.J., and Pellerin L. Quantitative RT-PCR analysis of uncoupling protein isoforms in mouse brain cortex: methodological optimization and comparison of expression with brown adipose tissue and skeletal muscle. J. Cereb. Blood Flow Metab. 24 (2004) 780-788
31. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(- Delta Delta C(T)) Method. Methods 25 (2001) 402-408
32. Lowry O.H., Rosenbrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
33. 9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23 (1989) 73-81
34. McKallip R.J., Nagarkatti M., and Nagarkatti P.S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 174 (2005) 3281-3289
35. Marchalant Y., Rosi S., and Wenk G.L. Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. Neuroscience 144 (2007) 1516-1522
36. Menetrey A., Augsburger M., Favrat B., Pin M.A., Rothuizen L.E., Appenzeller M., Buclin T., Mangin P., and Giroud C. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a Cannabis decoction made with 20 or 60 mg Delta9-THC. J. Anal. Toxicol. 29 (2005) 327-338
37. Molina-Holgado F., Molina-Holgado E., and Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett. 433 (1998) 139-142
38. Molina-Holgado E., Vela J.M., Arévalo-Martin A., Almazan G., Molina-Holgado F., Borrell J., and Guaza C. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinas/Akt signaling. J. Neurosci. 22 (2002) 9742-9753
39. Molina-Holgado F., Pinteaux E., Moore J.D., Molina-Holgado E., Guaza C., Gibson F.L., and Rothwell N.J. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23 (2003) 6470-6474
40. Monnet-Tschudi F., Zurich M.G., and Honegger P. Evaluation of the toxicity of different metal compounds in the developing brain using aggregating cell cultures as a model. Toxicol. In Vitro 7 (1993) 335-339
41. Monnet-Tschudi F., Zurich M.G., Schilter B., Costa L.G., and Honegger P. Maturation-dependent effects of chlorpyrifos and parathion and their oxygen analogs on acetylcholinesterase and neuronal and glial markers in aggregating brain cell cultures. Toxicol. Appl. Pharmacol. 165 (2000) 175-183
42. Mura P., Kintz P., Dumestre V., Raul S., and Hauet T. THC can be detected in brain while absent in blood. J. Anal. Toxicol. 29 (2005) 842-843
43. Pertwee R.G. Cannabinoids and multiple sclerosis. Pharmacol. Ther. 95 (2002) 165-174
44. Pishak M.R., and Phillips A.T. A modified radioisotopic assay for measuring glutamine synthetase activity in tissue extracts. Anal. Biochem. 94 (1979) 82-88
45. Pryce G., Ahmed Z., Hankey D.J.R., Jackson S.J., Croxford J.L., Pocock J.M., Ledent C., Petzold A., Thompson A.J., Giovannoni G., Cuzner L., and Baker D. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126 (2003) 2191-2202
46. Ramaekers J.G., Moeller M.R., van Ruitenbeek P., Theunissen E.L., Schneider E., and Kauert G. Cognition and motor control as a function of Delta-9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend. 85 (2006) 114-122
47. Ramirez B.G., Blazquez C., Gomez del Pulgar T., Guzman M., and de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 (2005) 1904-1913
48. Sheng W.S., Hu S., Min X., Cabral G.A., Lokensgard J.R., and Peterson P.K. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49 (2005) 211-219
49. Strahm E., Saudan C., Sottas P.E., Mangin P., and Saugy M. Direct detection and quantification of 19-norandrosterone sulfate in human urine by liquid chromatography-linear ion trap mass spectrometry. J. Chromatogr., B 852 (2007) 491-496
50. Vaney C., Heinzel-Gutenbrunner M., Jobin P., Tschopp F., Gattlen B., Hagen U., Schnelle M., and Reif M. Efficacy, safety and tolerability of an orally administered Cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomised, double-blind, placebo-controlled, crossover study. Mult. Scler. 10 (2004) 417-424
51. Van Wagoner N.J., and Benveniste E.N. Interleukin-6 expression and regulation in astrocytes. J. Neuroimmunol. 100 (1999) 124-139
52. Wilson S.H., Schrier B.K., and Farber J.L. Markers for gene expression in cultured cells from the nervous system. J. Biol. Chem. 247 (1972) 3159-3169
53. Zurich M.-G., Monnet-Tschudi F., Bérode M., and Honegger P. Lead acetate toxicity in vitro: dependence on cell composition of the cultures. Toxicol. In Vitro 12 (1998) 191-196
54. Zurich M.G., Honegger P., Schilter B., Costa L.G., and Monnet-Tschudi F. Involvement of glial cells in the neurotoxicity of parathion and chlorpyrifos. Toxicol. Appl. Pharmacol. 201 (2004) 97-104